“Since this year, the three major stock indexes of A-Shares have made a continuous correction, especially some popular track stocks with a large increase last year. They have fallen sharply under the pressure of profit taking, while undervalued blue chips have rebounded against the trend, and the style of the market has changed as scheduled.” Yang Delong, chief economist of Qianhai open source fund, told the Securities Daily.
According to the reporter’s combing, the Shanghai index fell by 3.22% during the month, during which a total of 3322 stocks showed an adjustment trend, accounting for 70.64% of the tradable stocks. 20 individual stocks, including Yingkou Jinchen Machinery Co.Ltd(603396) , Changjiang materials, Hunan Yujing Machinery Co.Ltd(002943) , Inner Mongolia Xinhua, Yanan Bicon Pharmaceutical Listed Company(002411) , Shaanxi Meibang Pharmaceutical Group Co.Ltd(605033) , were callback by more than 30% during the period.
In this context, some stocks bucked the market and strengthened. According to statistics, during the 14 trading days of the month, there were 65 A shares, and the share price of individual shares hit an all-time high.
Specifically, 65 stocks show two characteristics:
First, the performance is good. According to the forecast of 2021 annual report disclosed by 25 companies, a total of 24 companies have good performance, accounting for 96%. Among them, Beijing Hotgen Biotech Co.Ltd(688068) net profit is expected to achieve a year-on-year increase of 1996.97%. In addition, nine companies including Zangger mining, Andon Health Co.Ltd(002432) , Naipu Mining Machinery Co.Ltd(300818) , Yongxing Special Materials Technology Co.Ltd(002756) , Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) , Zhejiang Orient Gene Biotech Co.Ltd(688298) , China Zhenhua (Group) Science & Technology Co.Ltd(000733) , Beijing Cuiwei Tower Co.Ltd(603123) , Hangzhou Biotest Biotech Co.Ltd(688767) are expected to double their net profits year-on-year.
Secondly, the majority of small and medium-sized stocks. Even if the “February 8th market” of A-Shares was staged on Friday, heavyweights focused on protecting the market, and small and medium-sized stocks fell. However, according to the data of this month, among the 65 stocks, 48 stocks with the latest A-share market value of less than 9 billion yuan, accounting for 73.85%.
At the same time, the good track of individual stocks is also one of the important factors for the rise of their stock prices. The above 65 stocks are mainly concentrated in pharmaceutical, biological, mechanical equipment and other application level industries, involving 17 and 12 stocks respectively.
According to Li Yifeng, chief researcher of Guangzhou pebble investment pharmaceutical industry, “three medical” linkage and other policies drive industrial innovation. The aging population, the transfer of the global pharmaceutical industry, the blooming of innovative technologies and the acceleration of import substitution are the basis for supporting the strengthening of the pharmaceutical market.
Chen Mengjie, chief strategic analyst of YueKai Securities Research Institute, believes that the internal sector differentiation of the pharmaceutical industry is obvious, the profits of the generic pharmaceutical industry are thinning, the profits of the innovative drug industry are rising, a number of pharmaceutical enterprises with innovative drugs are gradually coming to the fore, the industry has eliminated the weeds and kept the turnips in the standardized and centralized development, and the competition pattern is expected to improve in the future.
Looking forward to the market of A-Shares next week, the industry said that there will still be obvious differentiation of a shares, and there will still be adjustment pressure for some overvalued varieties in the short term. However, with the support of undervalued varieties, the downside risk of the market is small. In addition, near the Spring Festival, the market volatility will begin to converge. It is expected that the market will rebound from the bottom and return to the annual line next week.
The figure shows a list of fundamentals of some high-profile stocks
tabulated by Xu Yiming
